Skip to content
value.today
Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

Total raised
$195 M
9 rounds on record
Latest round
$80 M
Mar 2021
First round on record
May 2011
Today
Went public
See the company page

Aura Biosciences, Inc. is listed today as Aura Biosciences, Inc.: market value, financials and filings are on its company page.

Funding rounds

9 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aura Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$80 MNo. 9$50 to $250 million

Aura Biosciences, Inc.: Raise no. 9, Mar 2021

Investors in this round

41 investors had bought by the notice of Apr 6, 2021: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Julie Feder · Executive Officer
  • David Johnson · Director
  • Giovanni Mariggi, Ph.D. · Director
  • Karan Takhar · Director
  • Raj Parekh, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Julie Feder, Secretary/CFO. Source: SEC Form D, newest notice filed Apr 6, 2021. Read the notice at the SEC.

equitySEC
Jun 2020$10 MNo. 8$10 to $50 million

Aura Biosciences, Inc.: Raise no. 8, Jun 2020

Investors in this round

32 investors had bought by the notice of Jul 9, 2020: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $17 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Julie Feder · Executive Officer
  • Art Pappas · Director
  • Casper Breum · Director
  • Christian Schetter · Director
  • George Golumbeski, Ph.D. · Director
  • Giovanni Mariggi, Ph.D. · Director
  • Joel Jean-Mairet, Ph.D. · Director
  • Raj Parekh, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Julie Feder, Secretary/CFO. Source: SEC Form D, newest notice filed Jul 9, 2020. Read the notice at the SEC.

equitySEC
Apr 2019$20 MNo. 7$10 to $50 million

Aura Biosciences, Inc.: Raise no. 7, Apr 2019

Investors in this round

36 investors had bought by the notice of Apr 12, 2019: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $40 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Julie E. Feder · Executive Officer
  • Lewis E. Geffen · Executive Officer
  • Alan E. Walts, Ph.D. · Director
  • Art E. Pappas · Director
  • Casper E. Breum · Director
  • Giovanni E. Mariggi, Ph.D. · Director
  • Joel E. Jean-Mairet, Ph.D. · Director
  • Mark E. Chin · Director
  • Raj E. Parekh, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Elisabet de los Pinos, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 12, 2019. Read the notice at the SEC.

equitySEC
Dec 2017$42 MNo. 6$10 to $50 million

Aura Biosciences, Inc.: Raise no. 6, Dec 2017

Investors in this round

42 investors had bought by the notice of Dec 13, 2018: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Julie E. Feder · Executive Officer
  • Lewis E. Geffen · Executive Officer
  • Alan E. Walts, Ph.D. · Director
  • Art E. Pappas · Director
  • Casper E. Breum · Director
  • Dale E. Pfost, Ph.D. · Director
  • Joel E. Jean-Mairet, Ph.D. · Director
  • Mark E. Chin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Elisabet de los Pinos, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 13, 2018. Read the notice at the SEC.

equitySEC
Sep 2016$12 MNo. 5$10 to $50 million

Aura Biosciences, Inc.: Raise no. 5, Sep 2016

Investors in this round

38 investors had bought by the notice of Nov 2, 2017: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Lewis E. Geffen · Executive Officer
  • Michael E. Wyzga · Executive Officer
  • Alan E. Walts, Ph.D. · Director
  • Art E. Pappas · Director
  • Dale E. Pfost, Ph.D. · Director
  • Joel E. Jean-Mairet, Ph.D. · Director
  • Jose' E. Baselga, Ph.D. · Director
  • Peter E. Wirth · Director
  • Raj E. Parekh, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Elisabet de los Pinos, Ph.D., Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 2, 2017. Read the notice at the SEC.

debt, optionsSEC
Feb 2015$21 MNo. 4$10 to $50 million

Aura Biosciences, Inc.: Raise no. 4, Feb 2015

Investors in this round

21 investors had bought by the notice of Mar 5, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $35 M offered; $13 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,212,500 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Peter B. Finn · Executive Officer · Secretary
  • Alan Walts, Ph.D. · Director · Executive Chairman of Board of Directors.
  • Art Pappas · Director
  • Dale Pfost, Ph.D. · Director
  • Javier Garcia · Director
  • Joel Jean-Mairet, Ph.D. · Director
  • Jose Baselga, Ph.D. · Director
  • Peter Wirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Of the total amount sold, $6,753,833.62 has been paid to the Company. The balance will be paid upon the happening of certain events.”
  • On the use of proceeds: “Executive Salaries and Director Compensation”

Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC.

equity, optionsSEC
Apr 2014$4 MNo. 3$2 to $10 million

Aura Biosciences, Inc.: Raise no. 3, Apr 2014

Investors in this round

41 investors had bought by the notice of Aug 14, 2014: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.d. · Executive Officer, Director · President and Treasurer
  • Peter B. Finn · Executive Officer · Secretary
  • Alan Walts · Director
  • Israel Ruiz · Director
  • Javier Garcia · Director
  • Jose Baselga, Ph.d. · Director
  • Peter B. Wirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Salaries”

Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Aug 14, 2014. Read the notice at the SEC.

equitySEC
Aug 2012$3 MNo. 2$2 to $10 million

Aura Biosciences, Inc.: Raise no. 2, Aug 2012

Investors in this round

22 investors had bought by the notice of Dec 26, 2012: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$5,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Peter B. Finn · Executive Officer
  • Israel B. Ruiz · Director
  • Jose Baselga, Ph.D. · Director
  • Pedro Granadillo · Director
  • Salvador B. Garcia-Atance · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Salaries”

Signed by Peter B. Finn, Secretary and General Counsel. Source: SEC Form D, newest notice filed Dec 26, 2012. Read the notice at the SEC.

equitySEC
May 2011$3 MNo. 1$2 to $10 million

Aura Biosciences, Inc.: Raise no. 1, May 2011

Investors in this round

23 investors had bought by the notice of Aug 26, 2011: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Aura Biosciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elisabet de los Pinos, Ph.D. · Executive Officer, Director
  • Peter C. Finn · Executive Officer
  • Edmundo Muniz, M.D., Ph.D. · Director
  • Lawrence C. Best · Director
  • Pedro Granadillo · Director
  • Salvador C. Garcia-Atance · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “salaries”

Signed by Peter B. Finn, Esq., Secretary and General Counsel. Source: SEC Form D, newest notice filed Aug 26, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aura Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).

    SEC Form D · Apr 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2021

That is all the official record says: Aura Biosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Aura Biosciences, Inc. are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Aura Biosciences, Inc.
InvestorKindAmountRoundRoleSource
Matrix Capital Management Company, LPFund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Medicxi Growth Co-Invest I LPFund or asset managernot statednot statedHeld Series D-1, D-2 and E preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Medicxi Growth I GP LtdCompanynot statednot statedHeld Series D-1, D-2 and E preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Medicxi Growth I LPFund or asset managernot statednot statedHeld Series D-1, D-2 and E preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Medicxi Ventures Management (Jersey) LtdFund or asset managernot statednot statedHeld Series D-1, D-2 and E preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 9 rounds above had up to 42 investors.

Largest shareholders today

Institutions holding Aura Biosciences, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aura Biosciences, Inc.
NameRoleNamed in
Elisabet de los Pinos, Ph.D.Executive officerApr 2021
Julie FederExecutive officerApr 2021
Julie E. FederExecutive officerApr 2019
Lewis E. GeffenExecutive officerApr 2019
Michael E. WyzgaExecutive officerJan 2018
Peter B. FinnSecretaryMar 2015
Elisabet de los Pinos, Ph.d.President and TreasurerAug 2014
Peter C. FinnExecutive officerAug 2011
David JohnsonDirectorApr 2021
Elisabet de los Pinos, Ph.D.DirectorApr 2021
Giovanni Mariggi, Ph.D.DirectorApr 2021
Karan TakharDirectorApr 2021
Raj Parekh, Ph.D.DirectorApr 2021
Art PappasDirectorJul 2020
Casper BreumDirectorJul 2020
Christian SchetterDirectorJul 2020
George Golumbeski, Ph.D.DirectorJul 2020
Joel Jean-Mairet, Ph.D.DirectorJul 2020
Alan E. Walts, Ph.D.DirectorApr 2019
Art E. PappasDirectorApr 2019
Casper E. BreumDirectorApr 2019
Giovanni E. Mariggi, Ph.D.DirectorApr 2019
Joel E. Jean-Mairet, Ph.D.DirectorApr 2019
Mark E. ChinDirectorApr 2019
Raj E. Parekh, Ph.D.DirectorApr 2019
Dale E. Pfost, Ph.D.DirectorDec 2018
Jose' E. Baselga, Ph.D.DirectorNov 2017
Peter E. WirthDirectorNov 2017
Henri E. TermeerDirectorSep 2016
Alan Walts, Ph.D.Executive Chairman of Board of Directors.Mar 2015
Dale Pfost, Ph.D.DirectorMar 2015
Javier GarciaDirectorMar 2015
Jose Baselga, Ph.D.DirectorMar 2015
Peter WirthDirectorMar 2015
Alan WaltsDirectorAug 2014
Elisabet de los Pinos, Ph.d.President and TreasurerAug 2014
Israel RuizDirectorAug 2014
Jose Baselga, Ph.d.DirectorAug 2014
Peter B. WirthDirectorAug 2014
Israel B. RuizDirectorDec 2012

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.